CVS Health
CVS
87.80
-0.15
-0.17%
CVS Health
US · CVS
#168 by market cap
Listed 1970
87.80
-0.15
-0.17%
Live - 5344 symbols - heartbeat 504s ago
· 2026-10-08 18:53
Pre-market
88.00
+0.06%
After-hours
85.10
-3.08%
Overnight
87.76
-0.22%
- Market cap
- 112.29B
- P/E (TTM)i
- 23.17
- P/Bi
- 1.41
- EPSi
- 1.39
- Div yieldi
- 3.03%
- 52W posi
- 47%
Reader sentiment
Are you bullish or bearish on CVS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 12 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.2 percentage points.
Institutional ownership
- Held by institutions
- 90.71% -0.16pp
- Institutions
- 2,369 -12
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund77.15%
Public Company4.12%
Hedge Fund3.35%
Government Pension Fund2.05%
Private Company1.53%
Sovereign Wealth Fund1.52%
Insurance Company0.51%
Family Office/Trust0.21%
Government0.10%
Other9.45%
Top holders as of 2026-06-30
BlackRock
9.63% · 123.22M sh
Capital Research
9.05% · 115.79M sh
Vanguard Capital Management, LLC
7.07% · 90.48M sh
State Street Global Advisors
4.71% · 60.28M sh
Dodge & Cox
3.91% · 50.01M sh
Other
65.61%
Wellington Management Group
2.64% · 33.80M sh
Geode Capital Management, LLC
2.34% · 29.90M sh
Vanguard Portfolio Management, LLC
2.08% · 26.64M sh
T. Rowe Price Group, Inc.
1.89% · 24.21M sh
FMR
1.79% · 22.95M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 30 buys · 20 sells
| Name | Role | Stake |
|---|---|---|
| Karen Lynch | Chief Executive Officer | 0.04% |
| C. Brown | Independent Director | 0.01% |
| Jean-Pierre Millon | Independent Director | 0.01% |
| J. Joyner | Executive Vice President & President of CVS Caremark | 0.01% |
| Prem Shah | Executive VP, Chief Pharmacy Officer and President of Pharmacy & Consumer Wellness | 0.01% |
| Michael Mahoney | Director | 0.00% |
| Nancy-Ann DeParle | Independent Director | 0.00% |
| Samrat Khichi | Executive VP, Chief Policy Officer & General Counsel | 0.00% |
| James Clark | Chief Accounting Officer | 0.00% |
| Anne Finucane | Independent Director | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-25 | James Clark | Chief Accounting Officer | Sale to Issuer | -454 | $90.98 |
| 2026-05-30 | Amy Compton-Phillips | Chief Medical Officer | Sale to Issuer | -7,618 | $90.98 |
| 2026-05-30 | Brian Newman | Chief Financial Officer | Sale to Issuer | -2,478 | $90.98 |
| 2026-05-20 | Roger Farah | Independent Chairperson | Intent to Sell (Form 144) | -2,817 | $93.68 |
| 2026-05-20 | Fernando Aguirre | Independent Director | Sale to Issuer | -32,000 | $93.50–93.78 |
| 2026-05-20 | Glenview Capital Management, LLC | -- | Open Market Disposition | -3,372,000 | $93.45–96.28 |
| 2026-05-20 | Glenview Capital Management, LLC | -- | Open Market Derivative Dispositi | -378,000 | $58.29 |
| 2026-05-19 | Fernando Aguirre | Independent Director | Intent to Sell (Form 144) | -32,000 | $94.69 |
| 2026-05-13 | Douglas Shulman | Director | Other Derivative Acquisition | +1,447 | -- |
| 2026-05-13 | J. Kirby | Director | Other Acquisition | +1,447 | $97.15 |
| 2026-05-13 | Lawrence Robbins | Director | Other Derivative Acquisition | +1,930 | -- |
| 2026-05-13 | Anne Finucane | Independent Director | Other Derivative Acquisition | +1,544 | -- |
| 2026-05-13 | C. Brown | Independent Director | Other Acquisition | +1,544 | $97.15 |
| 2026-05-13 | Alecia DeCoudreaux | Independent Director | Other Derivative Acquisition | +1,447 | -- |
| 2026-05-13 | Guy Sansone | Director | Other Acquisition | +1,447 | $97.15 |
| 2026-05-13 | Fernando Aguirre | Independent Director | Other Acquisition | +1,563 | $97.15 |
| 2026-05-13 | Jeffrey Balser | Independent Director | Other Acquisition | +2,058 | $97.15 |
| 2026-05-13 | Leslie Norwalk | Director | Other Acquisition | +1,447 | $97.15 |
| 2026-05-13 | John Gallina | Director | Other Derivative Acquisition | +1,447 | -- |
| 2026-05-13 | Michael Mahoney | Director | Other Derivative Acquisition | +1,737 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 18:53:36 · For reference only, not investment advice and not tailored to your situation.